gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2021-31-4-55-63gastro-j-638Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГОВ, ГЕПАТОЛОГОВNATIONAL COLLEGE OF GASTROENTEROLOGISTS, HEPATOLOGISTSАктуальные тенденции в лечении кислотозависимых заболеваний: клиническая эффективность и безопасность рабепразолаCurrent Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazolehttps://orcid.org/0000-0001-9608-0196ЛопинаО. Д.LopinaO. D.

Лопина Ольга Дмитриевна — доктор биологических наук, профессор кафедры биохимии биологического факультета

119234, г. Москва, Ленинские горы, д. 1, стр. 12

Olga D. Lopina — Dr. Sci. (Biol.), Prof., Chair of Biochemistry, Biology Faculty

119234, Moscow, Leninskie gory, 1, bld. 12

od_lopina@mail.ruhttps://orcid.org/0000-0003-2555-8644НургалиеваБ. К.NurgalievaB. K.

Нургалиева Баян Кадировна — доктор медицинских наук, Master de sante publique, заведующая курсом пропедевтики внутренних болезней; заведующая поликлиникой

050062, г. Алма-Ата, ул. Толе би, д. 94

Bayan K. Nurgalieva — Dr. Sci. (Med.), Master de SantéPublique, Leader of the Internal Medicine PropaedeuticsCourse; Head of Outpatient Clinic

050062, Almaty, Tole bi str., 94

bayan_n@mail.ruhttps://orcid.org/0000-0003-4456-8725ЛапинаТ. Л.LapinaT. L.

Лапина Татьяна Львовна* — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии

119435, г. Москва, ул. Погодинская, д. 1, стр. 1

Tatiana L. Lapina — Cand. Sci. (Med), Assoc. Prof., Chair of Internal Diseases Propedeutics, Gastroenterology and Hepatology

119435, Moscow, Pogodinskaya str., 1, bld. 1

tatlapina@gmail.comФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»РоссияLomonosov Moscow State UniversityRussian FederationКазахский Национальный медицинский университет им. С.Д. Асфендиярова; ТОО «Медицинский центр ХАК»КазахстанAsfendiyarov Kazakh National Medical University; KhAK Medical Centre LLPKazakhstanФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» (Сеченовский университет) Министерства здравоохранения Российской ФедерацииРоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2021201220213145563Copyright © Лопина О.Д., Нургалиева Б.К., Лапина Т.Л., 20212021Лопина О.Д., Нургалиева Б.К., Лапина Т.Л.Lopina O.D., Nurgalieva B.K., Lapina T.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/638

Цель обзора: представить данные об особенностях рабепразола в сравнении с другими ИПП, его эффективности и безопасности при лечении кислотозависимых заболеваний.Основное содержание: Рабепразол благодаря высоким значениям константы диссоциации (рКа) обеспечивает быстрое блокирование протонной помпы париетальной клетки. Меньшая зависимость метаболизма рабепразола от ферментной системы цитохрома Р-450 делает предсказуемым его антисекреторный эффект и снижает риск лекарственного взаимодействия с другими препаратами, метаболизирующимися с помощью этой системы. Более быстрое начало антисекреторного действия и более выраженная кислотосупрессивная активность рабепразола определяют его более высокую клиническую эффективность при лечении таких кислотозависимых заболеваний, как гастроэзофагеальная рефлюксная болезнь и язвенная болезнь. Это обусловливает предпочтительность назначения рабепразола (париета) в курсовом и поддерживающем лечении данных заболеваний, а также в эрадикационной терапии H. pylori.Заключение: особенности рабепразола, заключающиеся в высоком потенциале кислотосупрессии, стойком антисекреторном эффекте с первого дня терапии, неферментном пути метаболизма, плейотропном действии, обусловливают высокую эффективность данного препарата при лечении всего спектра кислотозависимых заболеваний и минимальный риск лекарственного взаимодействия.

Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (pKa). A lower rabeprazole metabolic dependence on cytochrome P-450 enzyme system renders its antisecretory effect predictable and reduces the risk of interactions with other drugs metabolised through this system. A faster antisecretory effect and higher acid-suppressive activity of rabeprazole determine its better clinical efficacy in treatment for such acid-dependent diseases as gastroesophageal reflux disease and peptic ulcer. This makes rabeprazole (Pariet) a preferred drug in course and maintenance therapies for acid-dependent diseases, as well as in H. pylori eradication.Conclusion. The rabeprazole properties of high acid suppression potential, persistent antisecretory effect from first day of therapy, non-enzymatic metabolism and pleiotropic action determine its high efficacy in treatment for a wide range of acid-dependent diseases at a minimal risk of drug interaction.

ингибиторы протонной помпырабепразолгастроэзофагеальная рефлюксная болезньязвенная болезньэрадикационная терапия H. pyloriбезопасностьдепрескрайбинг ингибиторов протонной помпыproton pump inhibitorsrabeprazolegastroesophageal reflux diseasepeptic ulcerH. pylori eradication therapysafetyproton pump inhibitor deprescribingReferencesИвашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Сторонова О.А., Зайратьянц О.В. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос журн гастроэнтерол гепатол колопроктол. 2020;30(4):70–97. DOI: 10.22416/1382-4376-2020-30-4-70-97Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zayratyants O.V., et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rus J Gastroenterol Hepatol Coloproctol. 2020;30(4):70–97 (In Russ.). DOI: 10.22416/1382-4376-2020-30-4-70-97Ивашкин В.Т., Маев И.В., Царьков П.В., Королев М.П., Андреев Д.Н., Баранская Е.К. и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Рос журн гастроэнтерол гепатол колопроктол. 2020;30(1):49–70. DOI: 10.22416/1382-4376-2020-30-1-49-70Ivashkin V.T., Maev I.V., Tsar’kov P.V., Korolev M.P., Andreev D.N., Baranskaya E.K., et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Rus J Gastroenterol Hepatol Coloproctol. 2020;30(1):49–70 (In Russ.). DOI: 10.22416/1382-4376-2020-30-1-49-70Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. Мартынов А.И., Яхно Н.Н., Арутюнов Г.П. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1–29. DOI: 10.14412/1995-4484-2018-1-29Karateev A.E., Nasonov E.L., Ivashkin V.T., Martynov A.I., Yakhno N.N., Arutyunov G.P., et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1–29 (In Russ.). DOI: 10.14412/1995-4484-2018-1-29Chiba T., Malfertheiner P., Satoh H. (eds). Proton Pump Inhibitors: A Balanced View. Front Gastrointest Res. Basel, Karger; 2013. DOI: 10.1159/isbn.978-3-318-02416-6Chiba T., Malfertheiner P., Satoh H. (eds). Proton Pump Inhibitors: A Balanced View. Front Gastrointest Res. Basel, Karger; 2013. DOI: 10.1159/isbn.978-3-318-02416-6Savarino V., Di Mario F., Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135–53. DOI: 10.1016/j.phrs.2008.09.016Savarino V., Di Mario F., Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135–53. DOI: 10.1016/j.phrs.2008.09.016Заборовский А.В., Маев И.В., Андреев Д.Н., Тарарина Л.А. Плейотропные эффекты рабепразола и их роль в лечении пациентов с кислотозависимыми заболеваниями. Рос журн гастроэнтерол гепатол колопроктол. 2017;27(3):18–26. DOI: 10.22416/1382-4376-2017-27-3-18-26Zaborovsky A.V., Mayev I.V., Andreyev D.N., Tararina L.A. Pleiotropic effects of rabeprazole at acid-related diseases. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(3):18–26 (In Russ.). DOI: 10.22416/1382-4376-2017-27-3-18-26Besancon M., Simon A., Sachs G., Shin J.M. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438–46. DOI: 10.1074/jbc.272.36.22438Besancon M., Simon A., Sachs G., Shin J.M. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438–46. DOI: 10.1074/jbc.272.36.22438Kromer W., Krüger U., Huber R., Hartmann M., Steinijans V.W. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56(2):57–70. DOI: 10.1159/000028183Kromer W., Krüger U., Huber R., Hartmann M., Steinijans V.W. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56(2):57–70. DOI: 10.1159/000028183Pantoflickova D., Dorta G., Jornod P., Ravie M., Blum A. Identification of the characteristics influencing the degree of antisecretory activity of PPIs. Gastroenterology. 2000;118(4):A1290. DOI: 10.1016/S0016-5085(00)81016-1Pantoflickova D., Dorta G., Jornod P., Ravie M., Blum A. Identification of the characteristics influencing the degree of antisecretory activity of PPIs. Gastroenterology. 2000;118(4):A1290. DOI: 10.1016/S0016-5085(00)81016-1Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13 Suppl 3:27–36. DOI: 10.1046/j.1365-2036.1999.00022.xIshizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13 Suppl 3:27–36. DOI: 10.1046/j.1365-2036.1999.00022.xSakai T., Aoyama N., Kita T., Sakaeda T., Nishiguchi K., Nishitora Y., et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001;18(6):721–7. DOI: 10.1023/A:1011035007591Sakai T., Aoyama N., Kita T., Sakaeda T., Nishiguchi K., Nishitora Y., et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001;18(6):721–7. DOI: 10.1023/A:1011035007591Zhang H.J., Zhang X.H., Liu J., Sun L.N., Shen Y.W., Zhou C. et al. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacol Res. 2020;152:104606. DOI: 10.1016/j.phrs.2019.104606Zhang H.J., Zhang X.H., Liu J., Sun L.N., Shen Y.W., Zhou C. et al. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacol Res. 2020;152:104606. DOI: 10.1016/j.phrs.2019.104606Kirchheiner J., Glatt S., Fuhr U., Klotz U., Meineke I., Seufferlein T., Brockmöller J. Relative potency of protonpump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65(1):19–31. DOI: 10.1007/s00228-008-0576-5Kirchheiner J., Glatt S., Fuhr U., Klotz U., Meineke I., Seufferlein T., Brockmöller J. Relative potency of protonpump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65(1):19–31. DOI: 10.1007/s00228-008-0576-5Caro J.J., Salas M., Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23(7):998–1017. DOI: 10.1016/s0149-2918(01)80087-4Caro J.J., Salas M., Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23(7):998–1017. DOI: 10.1016/s0149-2918(01)80087-4Zhang J.X., Ji M.Y., Song J., Lei H.B., Qiu S., Wang J., et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19(45):8408–19. DOI: 10.3748/wjg.v19.i45.8408Zhang J.X., Ji M.Y., Song J., Lei H.B., Qiu S., Wang J., et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19(45):8408–19. DOI: 10.3748/wjg.v19.i45.8408Khan Z., Alastal Y., Khan M.A., Khan M.S., Khalil B., Shrestha S., et al. On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2018;2018:6417526. DOI: 10.1155/2018/6417526Khan Z., Alastal Y., Khan M.A., Khan M.S., Khalil B., Shrestha S., et al. On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2018;2018:6417526. DOI: 10.1155/2018/6417526Инструкция по применению лекарственного препарата для медицинского применения Париет® (Periet®). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d12dc9d9-eb9d-4862-bbee49154a630b9d&t=Инструкция по применению лекарственного препарата для медицинского применения Париет® (Periet®). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d12dc9d9-eb9d-4862-bbee49154a630b9d&t=Robinson M., Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–54. DOI: 10.2165/00003495-200363240-00004Robinson M., Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–54. DOI: 10.2165/00003495-200363240-00004Pantoflickova D., Dorta G., Ravic M., Jornod P., Blum A.L. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17:1507–14. DOI: 10.1046/j.1365-2036.2003.01496.xPantoflickova D., Dorta G., Ravic M., Jornod P., Blum A.L. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17:1507–14. DOI: 10.1046/j.1365-2036.2003.01496.xRobinson M., Fitzgerald S., Hegedus R., Murthy A., Jokubaitis L.; FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, openlabel assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16(3):445–54. DOI: 10.1046/j.1365-2036.2002.01181.x. Erratum in: Aliment Pharmacol Ther 2002;16(5):1035.Robinson M., Fitzgerald S., Hegedus R., Murthy A., Jokubaitis L.; FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, openlabel assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16(3):445–54. DOI: 10.1046/j.1365-2036.2002.01181.x. Erratum in: Aliment Pharmacol Ther 2002;16(5):1035.Miner P., Orr W., Filippone J., Jokubaitis L., Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332–9. DOI: 10.1111/j.1572-0241.2002.05769.xMiner P., Orr W., Filippone J., Jokubaitis L., Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332–9. DOI: 10.1111/j.1572-0241.2002.05769.xDekkers C.P., Beker J.A., Thjodleifsson B., Gabryelewicz A., Bell N.E., Humphries T.J. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13(1):49–57. DOI: 10.1046/j.1365-2036.1999.00438.xDekkers C.P., Beker J.A., Thjodleifsson B., Gabryelewicz A., Bell N.E., Humphries T.J. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13(1):49–57. DOI: 10.1046/j.1365-2036.1999.00438.xBirbara C., Breiter J., Perdomo C., Hahne W. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000;12(8):889–97. DOI: 10.1097/00042737-200012080-00008Birbara C., Breiter J., Perdomo C., Hahne W. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000;12(8):889–97. DOI: 10.1097/00042737-200012080-00008Caos A., Moskovitz M., Dayal Y., Perdomo C., Niecestro R., Barth J. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Am J Gastroenterol. 2000;95(11):3081–8. DOI: 10.1111/j.1572-0241.2000.03179.xCaos A., Moskovitz M., Dayal Y., Perdomo C., Niecestro R., Barth J. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Am J Gastroenterol. 2000;95(11):3081–8. DOI: 10.1111/j.1572-0241.2000.03179.xBytzer P., Blum A., De Herdt D., Dubois D.; Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20(2):181–8. DOI: 10.1111/j.1365-2036.2004.01999.xBytzer P., Blum A., De Herdt D., Dubois D.; Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20(2):181–8. DOI: 10.1111/j.1365-2036.2004.01999.xKawara F., Fujita T., Morita Y., Uda A., Masuda A., Saito M., et al. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy. World J Gastroenterol. 2017;23(11):2060–7. DOI: 10.3748/wjg.v23.i11.2060Kawara F., Fujita T., Morita Y., Uda A., Masuda A., Saito M., et al. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy. World J Gastroenterol. 2017;23(11):2060–7. DOI: 10.3748/wjg.v23.i11.2060Ichikawa H., Sugimoto M., Sugimoto K., Andoh A., Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31(4):716–26. DOI: 10.1111/jgh.13233Ichikawa H., Sugimoto M., Sugimoto K., Andoh A., Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31(4):716–26. DOI: 10.1111/jgh.13233Saitoh T., Otsuka H., Kawasaki T., Endo H., Iga D., Tomimatsu M., et al. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology. 2009;56(91–92):703–6.Saitoh T., Otsuka H., Kawasaki T., Endo H., Iga D., Tomimatsu M., et al. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology. 2009;56(91–92):703–6.Burget D.W., Chiverton K.D., Hunt R.H. Is there an optimal degree of acid supression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99:345–51.Burget D.W., Chiverton K.D., Hunt R.H. Is there an optimal degree of acid supression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99:345–51.Абдулганиева Д.И. Вариабельность показателей суточной рН-метрии у пациентов с язвенной болезнью двенадцатиперстной кишки после однократного приема рабепразола. Рос журн гастроэнтерол гепатол колопроктол. 2010;20(6):76–80.Abdulganiyeva D.I. Variability of 24-hour pH-metry scores after single dose of rabeprazole. Rus J Gastroenterol Hepatol Coloproctol. 2010;20(6):76–90 (In Russ.).Dadabhai A., Friedenberg F.K. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf. 2009;8(1):119–26. DOI: 10.1517/14740330802622892Dadabhai A., Friedenberg F.K. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf. 2009;8(1):119–26. DOI: 10.1517/14740330802622892Dekkers C.P., Beker J.A., Thjodleifsson B., Gabryelewicz A., Bell N.E., Humphries T.J. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther. 1999;13(2):179–86. DOI: 10.1046/j.1365-2036.1999.00449.xDekkers C.P., Beker J.A., Thjodleifsson B., Gabryelewicz A., Bell N.E., Humphries T.J. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther. 1999;13(2):179–86. DOI: 10.1046/j.1365-2036.1999.00449.xИвашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол. 2018;28(1):55–70. DOI: 10.22416/1382-4376-2018-28-1-55-70Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya Y.K., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(1):55-70 (In Russ.). DOI: 10.22416/1382-4376-2018-28-1-55-70McNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gisbert J.P. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414–25. DOI: 10.1111/j.1365-2036.2012.05211.xMcNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gisbert J.P. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414–25. DOI: 10.1111/j.1365-2036.2012.05211.xMalfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6– 30. DOI: 10.1136/gutjnl-2016-312288Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6– 30. DOI: 10.1136/gutjnl-2016-312288Padol S., Yuan Y., Thabane M., Padol I.T., Hunt R.H. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101(7):1467–75. DOI: 10.1111/j.1572-0241.2006.00717.xPadol S., Yuan Y., Thabane M., Padol I.T., Hunt R.H. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101(7):1467–75. DOI: 10.1111/j.1572-0241.2006.00717.xTang H.L., Li Y., Hu Y.F., Xie H.G., Zhai S.D. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013;8:e62162. DOI: 10.1371/journal.pone.0062162Tang H.L., Li Y., Hu Y.F., Xie H.G., Zhai S.D. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013;8:e62162. DOI: 10.1371/journal.pone.0062162Morino Y., Sugimoto M., Nagata N., Niikiura R., Iwata E., Hamada M., et al. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front Pharmacol. 2021 Oct;12:759249. DOI: 10.3389/fphar.2021.759249Morino Y., Sugimoto M., Nagata N., Niikiura R., Iwata E., Hamada M., et al. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front Pharmacol. 2021 Oct;12:759249. DOI: 10.3389/fphar.2021.759249Tsutsui N., Taneike I., Ohara T., Goshi S., Kojio S., Iwakura N., et al. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother 2000;44(11):3069–73. DOI: 10.1128/AAC.44.11.3069-3073.2000Tsutsui N., Taneike I., Ohara T., Goshi S., Kojio S., Iwakura N., et al. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother 2000;44(11):3069–73. DOI: 10.1128/AAC.44.11.3069-3073.2000Ohara T., Goshi S., Taneike I., Tamura Y., Zhang H.M., Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001;6(2):125–9. DOI: 10.1046/j.1523-5378.2001.00018.xOhara T., Goshi S., Taneike I., Tamura Y., Zhang H.M., Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001;6(2):125–9. DOI: 10.1046/j.1523-5378.2001.00018.xZhang Z., Liu Z.Q., Zheng P.Y., Tang F.A., Yang P.C. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol 2010;16(10):1279–84. DOI: 10.3748/wjg.v16.i10.1279Zhang Z., Liu Z.Q., Zheng P.Y., Tang F.A., Yang P.C. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol 2010;16(10):1279–84. DOI: 10.3748/wjg.v16.i10.1279Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. WHO Technical Report Series. 2006;937 Annex ++*//7:347–90.Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. WHO Technical Report Series. 2006;937 Annex ++*//7:347–90.Соколов А., Кукес В., Бунятян Н., Родина Т., Прокофьев А., Архипов В. и др. Терапевтическая эквивалентность, биоэквивалентность и взаимозаменяемость лекарственных средств. Врач. 2015;10:32–5.Sokolov А., Kukes V., Bunatyan N., Rodina T., Prokofiev A., Arkhipov V., Krasnykh L., Sokova E. Therapeutic equivalence, bioequivalence and interchangeability of medicinal products. Vrach. 2015;10:32–5 (In Russ.).Горячев Д.В., Уварова Н.Е. Обоснование возможности проведения клинических исследований терапевтической эквивалентности. Ведомости Научного центра экспертизы средств медицинского применения. 2019;9(2):79–84. DOI: 10.30895/1991-2919-2019-9-2-79-84Goryachev D.V., Uvarova N.E. Assessment of the Feasibility of Therapeutic Equivalence Studies. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2019;9(2):79–84 (In Russ.). DOI: 10.30895/1991-2919-2019-9-2-79-84Зырянов С.К., Белоусов Ю.Б. Дженерики антибактериальных препаратов: за и против. Справочник поликлинического врача. 2012;5:11–3 [Zyryanov S.K., Belousov Yu.B. Antibacterial generics: pros and cons. Polyclinic Physician’s Handbook. 2012; 5: 11–3) (In Russ.)] .Zyryanov S.K., Belousov Yu.B. Antibacterial generics: pros and cons. Polyclinic Physician’s Handbook. 2012; 5: 11–3) (In Russ.) .Ukwueze S.E., Ogbokor M., Ezealisiji K.M. Quality Assessment of Different Brands of Rabeprazole Tablets Marketed In Some Nigerian Cities. J Pharm Chem Biol Sci. 2017;5(4):345–53.Ukwueze S.E., Ogbokor M., Ezealisiji K.M. Quality Assessment of Different Brands of Rabeprazole Tablets Marketed In Some Nigerian Cities. J Pharm Chem Biol Sci. 2017;5(4):345–53.Передерий В.Г., Пучков К.С., Чернявский В.В., Чичула Е.В. Сравнительная антисекреторная эффективность оригинального и генерического рабепразола у больных с ГЭРБ по данным суточного рН-мониторинга желудка. Здоровье Украины. 2006;15:148–54Perederiy V.G., Puchkov K.S., Chernyavskiy V.V., Chichula E.V. Comparative antisecretory efficacy of original vs. generic rabeprazole in GERD patients according to 24-h gastric pH-monitoring. Zdorovye Ukrainy, 2006; 15, 148-154. (In Russ.).Lanas-Gimeno A., Hijos G., Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf. 2019;18(11):1043–53. DOI: 10.1080/14740338.2019.1664470Lanas-Gimeno A., Hijos G., Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf. 2019;18(11):1043–53. DOI: 10.1080/14740338.2019.1664470Corsonello A., Lattanzio F., Bustacchini S., Garasto S., Cozza A., Schepisi R., et al. Adverse Events of Proton Pump Inhibitors: Potential Mechanisms. Curr Drug Metab. 2018;19(2):142–54. DOI: 10.2174/1389200219666171207125351Corsonello A., Lattanzio F., Bustacchini S., Garasto S., Cozza A., Schepisi R., et al. Adverse Events of Proton Pump Inhibitors: Potential Mechanisms. Curr Drug Metab. 2018;19(2):142–54. DOI: 10.2174/1389200219666171207125351Ивашкин В.Т., Маев И.В., Трухманов А.С., Шептулин А.А., Симаненков В.И., Лапина Т.Л. и др. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной Российской гастроэнтерологической недели). Рос журн гастроэнтерол гепатол колопроктол. 2020;30(6):7–18. DOI: 10.22416/1382-4376-2020-30-6-7-18Ivashkin V.T., Maev I.V., Trukhmanov A.S., Sheptulin A.A., Simanenkov V.I., Lapina T.L., et al. Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week). Rus J Gastroenterol Hepatol Coloproctol. 2020;30(6):7–18. (In Russ.). DOI: 10.22416/1382-4376-2020-30-6-7-18Caos A., Breiter J., Perdomo C., Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005 Aug 1;22(3):193–202. DOI: 10.1111/j.1365-2036.2005.02555.xCaos A., Breiter J., Perdomo C., Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005 Aug 1;22(3):193–202. DOI: 10.1111/j.1365-2036.2005.02555.xHelgadottir H., Bjornsson E.S. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci. 2019;20(21):5469. DOI: 10.3390/ijms20215469Helgadottir H., Bjornsson E.S. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci. 2019;20(21):5469. DOI: 10.3390/ijms20215469Wang Z.Y., Chen M., Zhu L.L., Yu L.S., Zeng S., Xiang M.X., Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449–67. DOI: 10.2147/TCRM.S80437Wang Z.Y., Chen M., Zhu L.L., Yu L.S., Zeng S., Xiang M.X., Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449–67. DOI: 10.2147/TCRM.S80437Lodato F., Azzaroli F,. Di Girolamo M., Feletti V., Cecinato P., Lisotti A., et al. Proton pump inhibitors in cirrhosis: Tradition or evidence based practice? World J Gastroenterol 2008;14(19):2980–5. DOI: 10.3748/wjg.14.2980Lodato F., Azzaroli F,. Di Girolamo M., Feletti V., Cecinato P., Lisotti A., et al. Proton pump inhibitors in cirrhosis: Tradition or evidence based practice? World J Gastroenterol 2008;14(19):2980–5. DOI: 10.3748/wjg.14.2980Freedberg D.E., Kim L.S., Yang Y.X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15. DOI: 10.1053/j.gastro.2017.01.031Freedberg D.E., Kim L.S., Yang Y.X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15. DOI: 10.1053/j.gastro.2017.01.031Ponce J., Argüello L., Bastida G., Ponce M., Ortiz V., Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci. 2004;49(6):931–6. DOI: 10.1023/b:ddas.0000034551.39324.c3Ponce J., Argüello L., Bastida G., Ponce M., Ortiz V., Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci. 2004;49(6):931–6. DOI: 10.1023/b:ddas.0000034551.39324.c3

The authors declare that there are no conflicts of interest present.